DexCom (DXCM) : The total negative money flow of $9.55 million on Tuesday indicates selling on strength. The inflow of money on upticks was $10.13 million, compared to $19.69 million outflow on downticks, which confirms distribution in the stock. The up to down ratio was 0.51. The negative money flow of $9.94 million in block trades reveals that the informed traders sold the stock on every bit of price strength.The transaction value of block trade on downtick was $9.94 million. The price action in the DexCom (DXCM) stock suggests that both the bulls and the bears were in equilibrium. The stock traded at $92.13 with a gain of $0.48 , a change of 0.52% over the previous days close. The stock registered 0.98% for the week.
Also, Deutsche Bank maintains its rating on DexCom (NASDAQ:DXCM). The global brokerage major raises the current price target from $90 per share to $98 per share. Analysts at the Deutsche Bank have a current rating of Buy on the shares. The rating by the firm was issued on July 15, 2016.
Shares of DexCom, Inc. appreciated by 0.04% during the last five trading days but lost 0.56% on a 4-week basis. DexCom, Inc. is up 42.86% in the last 3-month period. Year-to-Date the stock performance stands at 12.49%.
DexCom (NASDAQ:DXCM): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $91.65 and $91.37 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $92.47. The buying momentum continued till the end and the stock did not give up its gains. It closed at $92.13, notching a gain of 0.52% for the day. The total traded volume was 647,563 . The stock had closed at $91.65 on the previous day.
In a related news, Sayer Kevin R, director officer (President & CEO) of Dexcom Inc, unloaded 7,000 shares at an average price of $90.78 on August 15, 2016. The total amount of the transaction was worth $635,460, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4, DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patients receiver and an application on the patients iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers, who can remotely monitor a patients glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpots data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.